Wei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wei Li has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Chenlu Xiao
Department of Laboratory Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication- Dan Qiao
Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
1 shared publication Dongjiang Wang
Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
1 shared publicationEnhua Sun
Department of Clinical Laboratory, Qilu Hospital of Shandong University
1 shared publicationFuyao Hu
Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong, China
1 shared publication- Hongwei Pan
Department of Clinical Laboratory, Qilu Hospital of Shandong University, China
1 shared publication
Latest Publications
- Open Access
- 11 November 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 2014277
Genomic characterization and early macrophage inflammatory responses to an emerging Mycobacterium wolinskyi isolate
Mycobacterium wolinskyi is an emerging rapidly growing nontuberculous mycobacterium increasingly recognized as a cause of skin, soft-tissue, and device-associated infections, including infections in immunocompetent individuals. However, its genomic characteristics and interactions with host immune cells remain poorly understood. In this study, we characterized a clinical M. wolinskyi isolate, designated QL01, recovered from a facial skin infection in an 11-year-old child, by combining antimicrobial susceptibility testing, whole-genome sequencing, comparative genomic analysis, and macrophage infection assays with transcriptomic profiling. QL01 was resistant to clarithromycin, imipenem, and trimethoprim-sulfamethoxazole, while remaining susceptible to amikacin, linezolid, moxifloxacin, minocycline, and doxycycline. Whole-genome sequencing generated a complete circular chromosome and identified antimicrobial resistance-associated homologs and host interaction-associated homologs. Comparative analysis revealed variable conservation of type VII secretion system (T7SS)- and Mce-associated loci among representative rapidly growing mycobacteria. Following uptake by mouse bone marrow-derived macrophages, viable intracellular QL01 remained recoverable after 24 h. RNA sequencing revealed an early innate immune and pro-inflammatory transcriptional response, with enrichment of TNF, NF-κB, Toll-like receptor, and C-type lectin receptor signaling pathways. RT-qPCR further confirmed increased expression of Ccl2 , Tnf , Il1b , Tlr2 , Clec4e , and Tnfaip3 . ELISA confirmed increased secretion of TNF-α, IL-1β, and IFN-β. Inhibition of IKK/NF-κB signaling attenuated QL01-induced phosphorylation of p65 and IκBα and reduced inflammatory cytokine secretion. These findings characterize the genomic features of a clinical M. wolinskyi isolate and describe the early macrophage response to this emerging nontuberculous mycobacterial species.
- 11 November 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 2014277
Open AccessGenomic characterization and early macrophage inflammatory responses to an emerging Mycobacterium wolinskyi isolate
Mycobacterium wolinskyi is an emerging rapidly growing nontuberculous mycobacterium increasingly recognized as a cause of skin, soft-tissue, and device-associated infections, including infections in immunocompetent individuals. However, its genomic characteristics and interactions with host immune cells remain poorly understood. In this study, we characterized a clinical M. wolinskyi isolate, designated QL01, recovered from a facial skin infection in an 11-year-old child, by combining antimicrobial susceptibility testing, whole-genome sequencing, comparative genomic analysis, and macrophage infection assays with transcriptomic profiling. QL01 was resistant to clarithromycin, imipenem, and trimethoprim-sulfamethoxazole, while remaining susceptible to amikacin, linezolid, moxifloxacin, minocycline, and doxycycline. Whole-genome sequencing generated a complete circular chromosome and identified antimicrobial resistance-associated homologs and host interaction-associated homologs. Comparative analysis revealed variable conservation of type VII secretion system (T7SS)- and Mce-associated loci among representative rapidly growing mycobacteria. Following uptake by mouse bone marrow-derived macrophages, viable intracellular QL01 remained recoverable after 24 h. RNA sequencing revealed an early innate immune and pro-inflammatory transcriptional response, with enrichment of TNF, NF-κB, Toll-like receptor, and C-type lectin receptor signaling pathways. RT-qPCR further confirmed increased expression of Ccl2 , Tnf , Il1b , Tlr2 , Clec4e , and Tnfaip3 . ELISA confirmed increased secretion of TNF-α, IL-1β, and IFN-β. Inhibition of IKK/NF-κB signaling attenuated QL01-induced phosphorylation of p65 and IκBα and reduced inflammatory cytokine secretion. These findings characterize the genomic features of a clinical M. wolinskyi isolate and describe the early macrophage response to this emerging nontuberculous mycobacterial species.
- Open Access
- 11 July 2026
- Published by Elsevier in Journal of Infection
- Vol. 93 (2) , 106810
Within-host evolution of tandemly duplicated blaKPC14 conferring cross-resistance to ceftazidime-avibactam, cefiderocol and aztreonam-avibactam in hypervirulent ST11 Klebsiella pneumoniae
- 11 July 2026
- Published by Elsevier in Journal of Infection
- Vol. 93 (2) , 106810
Open AccessWithin-host evolution of tandemly duplicated blaKPC14 conferring cross-resistance to ceftazidime-avibactam, cefiderocol and aztreonam-avibactam in hypervirulent ST11 Klebsiella pneumoniae
- Open Access
- 29 November 2023
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (2) , 249-257
Performance of the Aspergillus galactomannan lateral flow assay with a digital reader for the diagnosis of invasive aspergillosis: a multicenter study
Purpose: The objective of this multicenter study was to compare the diagnostic performance of lateral flow assay (LFA) and enzyme-linked immunosorbent assay (ELISA) to detect the Dynamiker Aspergillus Galactomannan levels in serum and bronchoalveolar lavage fluid (BALF) samples for I. Methods: We registered 310 clinically suspected Aspergillus infection patients from December 2021 to February 2023 and classified them into subgroups as the “IA group” and “non-IA group” based on the latest EORTC/MSG guidelines. The immunoassays were analyzed by LFA and ELISA respectively. Results: Galactomannan was examined using LFA, and serum and BALF samples demonstrated sensitivities of 82.57% and 89.47%, specificities of 90.76% and 92.00%, PPVs of 89.11% and 96.23%, and NPVs of 85.04% and 79.31%, respectively. Galactomannan was observed using two assays in serum and BALF samples and showed PPAs of 95.11% and 93.33%, NPAs of 89.19% and 96.30%, and TPAs of 92.47% and 94.25%, respectively. The ROC curve demonstrated that LFA had optimum diagnostic value when the index value (I value) = 0.5, the sensitivity was 84.94%, and the specificity was 90.97%. Conclusion: Compared to the ELISA method, the LFA has shown excellent performance for the diagnosis of IA in serum and BALF sample and can be used as an assay for the early diagnosis of patients with IA. The dynamic change in galactomannan levels may be useful for assessing treatment response.
- 29 November 2023
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (2) , 249-257
Open AccessPerformance of the Aspergillus galactomannan lateral flow assay with a digital reader for the diagnosis of invasive aspergillosis: a multicenter study
Purpose: The objective of this multicenter study was to compare the diagnostic performance of lateral flow assay (LFA) and enzyme-linked immunosorbent assay (ELISA) to detect the Dynamiker Aspergillus Galactomannan levels in serum and bronchoalveolar lavage fluid (BALF) samples for I. Methods: We registered 310 clinically suspected Aspergillus infection patients from December 2021 to February 2023 and classified them into subgroups as the “IA group” and “non-IA group” based on the latest EORTC/MSG guidelines. The immunoassays were analyzed by LFA and ELISA respectively. Results: Galactomannan was examined using LFA, and serum and BALF samples demonstrated sensitivities of 82.57% and 89.47%, specificities of 90.76% and 92.00%, PPVs of 89.11% and 96.23%, and NPVs of 85.04% and 79.31%, respectively. Galactomannan was observed using two assays in serum and BALF samples and showed PPAs of 95.11% and 93.33%, NPAs of 89.19% and 96.30%, and TPAs of 92.47% and 94.25%, respectively. The ROC curve demonstrated that LFA had optimum diagnostic value when the index value (I value) = 0.5, the sensitivity was 84.94%, and the specificity was 90.97%. Conclusion: Compared to the ELISA method, the LFA has shown excellent performance for the diagnosis of IA in serum and BALF sample and can be used as an assay for the early diagnosis of patients with IA. The dynamic change in galactomannan levels may be useful for assessing treatment response.